Mysthera Therapeutics AG made its debut in Switzerland on 21 August with $3.5 million of seed capital and a plan to develop new therapies for autoimmune diseases. The company is being supported by Forty51 Ventures, a Basel-based venture capital firm focused on early-stage investments in biotech with a geographic emphasis on Switzerland, France and Germany.
